Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Breast Cancer | Review

Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review

Authors: Liu Tang, Haifei Xu, Tong Wu, Wenhao Wu, Yuhao Lu, Jijia Gu, Xiaoling Wang, Mei Zhou, Qiuyang Chen, Xuan Sun, Hongzhou Cai

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Bladder cancer is one of the most frequent malignant tumors of the urinary system. The prevalence of bladder cancer among men and women is roughly 5:2, and both its incidence and death have been rising steadily over the past few years. At the moment, metastasis and recurrence of advanced bladder cancer—which are believed to be connected to the malfunction of multigene and multilevel cell signaling network—remain the leading causes of bladder cancer-related death. The therapeutic treatment of bladder cancer will be greatly aided by the elucidation of these mechanisms. New concepts for the treatment of bladder cancer have been made possible by the advancement of research technologies and a number of new treatment options, including immunotherapy and targeted therapy. In this paper, we will extensively review the development of the tumor microenvironment and the possible molecular mechanisms of bladder cancer.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Li HZ, Zheng RS, Du LB, Zhang SW, Zhu C, Wei WW, He J. Bladder cancer incidence, mortality and temporal trends in China. Zhonghua Zhong Liu Za Zhi. 2021;43(3):293–8.PubMed
3.
4.
5.
Burger M, Catto J, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, Vecchia CL, Shariat S. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–41.PubMedCrossRef
6.
Farling KB. Bladder cancer: Risk factors, diagnosis, and management. Nurse Pract. 2017;42(3):26–33.PubMedCrossRef
7.
Rice TW, Ishwaran H, Hofstetter WL, Kelsen DP, Apperson-Hansen C, Blackstone EH & Worldwide Esophageal Cancer Collaboration Investigators. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29(8):897–905. https://​doi.​org/​10.​1111/​dote.​12533.
8.
Daskivich TJ, Chamie K, Litwin MS, Deapen D, Ballon-Landa E. Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. Cancer J Am Cancer Soc. 2015;121:379–85.
9.
10.
Spano D, Zollo M. Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis. 2012;29(4):381–95.PubMedCrossRef
11.
Hatogai K, Sweis RF. The tumor microenvironment of bladder cancer. In: Birbrair A, editor. Tumor microenvironments in organs, vol. 1296. Springer International Publishing: Cham; 2020. p. 275–90.CrossRef
12.
13.
Zhang H, Ye Y-L, Li M-X, Ye S-B, Huang W-R, Cai T-T, He J, Peng J-Y, Duan T-H, Cui J, Zhang X-S, Zhou F-J, Wang R-F, Li J. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene. 2017;36(15):2095–104.PubMedCrossRef
14.
Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi A-S, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derré L. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Investig. 2017;127(8):2916–29.PubMedPubMedCentralCrossRef
15.
Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012;130(5):1109–19.PubMedCrossRef
16.
Mariano LL, Ingersoll MA. Bladder resident macrophages: mucosal sentinels. Cell Immunol. 2018;330:136–41.CrossRef
17.
Leblond MM, Zdimerova H, Desponds E, Verdeil G. Tumor-associated macrophages in bladder cancer: biological role, impact on therapeutic response and perspectives for immunotherapy. Cancers. 2021;13:4712.PubMedPubMedCentralCrossRef
18.
19.
Sharifi L, Nowroozi MR, Amini E, Arami MK, Ayati M, Mohsenzadegan M. A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting. Int Immunopharmacol. 2019;76: 105880.PubMedCrossRef
20.
Leblond MM, Zdimerova H, Desponds E, Verdeil G. Tumor-associated macrophages in bladder cancer: biological role, impact on therapeutic response and perspectives for immunotherapy. Cancers (Basel). 2021;13(18):4712.PubMedCrossRef
21.
Zhu J, Zhi Q, Zhou BP, Tao M, Liu J, Li W. The role of tumor associated macrophages in the tumor microenvironment: mechanism and functions. Anticancer Agents Med Chem. 2016;16(9):1133–41.PubMedCrossRef
22.
Zhang Q, Mao Z, Sun J. NF-κB inhibitor, BAY11-7082, suppresses M2 tumor-associated macrophage induced EMT potential via miR-30a/NF-κB/Snail signaling in bladder cancer cells. Gene. 2019;710:91–7.PubMedCrossRef
23.
Zhao Y, Wang D, Xu T, Liu P, Cao Y, Wang Y, Yang X, Xu X, Wang X, Niu H. Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment. Oncotarget. 2015;6(36):39196–210.PubMedPubMedCentralCrossRef
24.
25.
Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503.PubMedCrossRef
26.
Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, Rubinstein J, Halachmi S. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol. 2015;33(2):67.e1-7.PubMedCrossRef
27.
Ozyalvacli ME, Ozyalvacli G, Kocaaslan R, Cecen K, Uyeturk U, Kemahlı E, Gucuk A. Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer. Can Urol Assoc J. 2015;9(3–4):E126–31.PubMedPubMedCentralCrossRef
28.
Favilla V, Castelli T, Urzì D, Reale G, Privitera S, Salici A, Russo GI, Cimino S, Morgia G. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study. Int Braz J Urol. 2016;42(4):685–93.PubMedPubMedCentralCrossRef
29.
Albayrak S, Zengin K, Tanik S, Atar M, Unal SH, Imamoglu MA, Gurdal M. Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer? Kaohsiung J Med Sci. 2016;32(6):327–33.PubMedCrossRef
30.
Okita K, Hatakeyama S, Momota M, Soma O, Hamano I, Tanaka T, Iwamura H, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Kawaguchi T, Ohyama C. Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer. Int J Urol. 2020;27(8):649–54.PubMedCrossRef
31.
Wang T, Yang Y, Wang Z, Zhang X, Li D, Wei J. A SNP of miR-146a is involved in bladder cancer relapse by affecting the function of bladder cancer stem cells via the miR-146a signallings. J Cell Mol Med. 2020;24(15):8545–56.PubMedPubMedCentralCrossRef
32.
Mumcu G, Cimilli H, Karacayli Ü, Inanc N, Türe-Özdemir F, Eksioglu-Demiralp E, Ergun T, Direskeneli H. Salivary levels of HNP 1–3 are related to oral ulcer activity in Behçet’s disease. Int J Dermatol. 2013;52(10):1198–201.PubMedCrossRef
33.
34.
35.
36.
37.
Yang Z, Xu Y, Bi Y, Zhang N, Wang H, Xing T, Bai S, Shen Z, Naz F, Zhang Z, Yin L, Shi M, Wang L, Wang L, Wang S, Xu L, Su X, Wu S, Yu C. Immune escape mechanisms and immunotherapy of urothelial bladder cancer. J Clin Transl Res. 2021;7(4):485–500.PubMedPubMedCentral
38.
Xiu W, Luo J. CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling. BMC Immunol. 2021;22(1):3.PubMedPubMedCentralCrossRef
39.
Horn T, Laus J, Seitz A, Maurer T, Schmid S, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, Gschwend J, Kübler H, Slotta-Huspenina J. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34(2):181–7.PubMedCrossRef
40.
41.
42.
Karimi M, Heshmati M, Fattahi S, Bagheri N, Alibeigi F, Taheri F, Anjomshoa M, Jami M, Ghatreh Samani M. The relation between the ghrelin receptor and FOXP3 in bladder cancer. Biotech Histochem. 2021;96(4):287–95.PubMedCrossRef
43.
Enokida T, Nishikawa H. Regulatory T cells: a target in anticancer immunotherapy. Nihon Rinsho. 2017;75(2):181–187.
44.
45.
Tao L, Qiu J, Jiang M, Song W, Yeh S, Yu H, Zang L, Xia S, Chang C. Infiltrating T cells promote bladder cancer progression via increasing IL1→androgen receptor→HIF1α→VEGFa signals. Mol Cancer Ther. 2016;15(8):1943–51.PubMedPubMedCentralCrossRef
46.
47.
Winerdal ME, Krantz D, Hartana CA, Zirakzadeh AA, Linton L, Bergman EA, Rosenblatt R, Vasko J, Alamdari F, Hansson J, Holmström B, Johansson M, Winerdal M, Marits P, Sherif A, Winqvist O. Urinary bladder cancer tregs suppress MMP2 and potentially regulate invasiveness. Cancer Immunol Res. 2018;6(5):528–38.PubMedCrossRef
48.
Gascoigne NR, Rybakin V, Acuto O, Brzostek J. TCR signal strength and T cell development. Annu Rev Cell Dev Biol. 2016;32:327–48.PubMedCrossRef
49.
Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, Smith M, Herrera PS, Chang HY, Satpathy AT, van den Brink MRM, Cross JR, Thompson CB. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21(9):1022–33.PubMedPubMedCentralCrossRef
50.
Lanier LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immunol Rev. 1997;155:145–54.PubMedCrossRef
51.
Zirakzadeh AA, Sherif A, Rosenblatt R, Ahlén Bergman E, Winerdal M, Yang D, Cederwall J, Jakobsson V, Hyllienmark M, Winqvist O, Marits P. Tumour-associated B cells in urothelial urinary bladder cancer. Scand J Immunol. 2020;91(2): e12830.PubMedCrossRef
52.
Ou Z, Wang Y, Liu L, Li L, Yeh S, Qi L, Chang C. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. Oncotarget. 2015;6(28):26065–78.PubMedPubMedCentralCrossRef
53.
Gupta SL, Khan N, Basu S, Soni V. B-cell-based immunotherapy: a promising new alternative. Vaccines (Basel). 2022;10(6):879.PubMedCrossRef
54.
Esteso G, Aguiló N, Julián E, Ashiru O, Ho MM, Martín C, Valés-Gómez M. Natural killer anti-tumor activity can be achieved by in vitro incubation with heat-killed BCG. Front Immunol. 2021;12: 622995.PubMedPubMedCentralCrossRef
55.
56.
Sun Y, Sedgwick AJ, Khan MA-A-K, Palarasah Y, Mangiola S, Barrow AD. A transcriptional signature of IL-2 expanded natural killer cells predicts more favorable prognosis in bladder cancer. Front Immunol. 2021;12: 724107.PubMedPubMedCentralCrossRef
57.
Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159–66.PubMedPubMedCentralCrossRef
58.
Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10):781–90.PubMedCrossRef
59.
Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007;7(9):737–44.PubMedCrossRef
60.
61.
Valés-Gómez M. NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation. Front Immunol. 2015;6:12.
62.
63.
Steinberg MW, Cheung TC, Ware CF. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation: HVEM networks in disease. Immunol Rev. 2011;244(1):169–87.PubMedPubMedCentralCrossRef
64.
Cheung TC, Steinberg MW, Oborne LM, Macauley MG, Fukuyama S, Sanjo H, D’Souza C, Norris PS, Pfeffer K, Murphy KM, Kronenberg M, Spear PG, Ware CF. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci. 2009;106(15):6244–9.PubMedPubMedCentralCrossRef
65.
Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen S-F, Hsieh S-L, Nagata S, Ni J, Chen L. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2000;164(8):4105–10.PubMedCrossRef
66.
Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu G-L, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, Spear PG, Ware CF. LIGHT, a new member of the TNF superfamily, and lymphotoxin ␣ are ligands for herpesvirus entry mediator. Immun.1998;8(1):21–30. https://​doi.​org/​10.​1016/​s1074-7613(00)80455-0.
67.
Fan Z, Yu P, Wang Y, Wang Y, Fu ML, Liu W, Sun Y, Fu Y-X. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood. 2006;107(4):1342–51.PubMedPubMedCentralCrossRef
68.
Suttmann H, Jacobsen M, Reiss K, Jocham D, Böhle A, Brandau S. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol. 2004;172(4 Pt 1):1490–5.PubMedCrossRef
69.
Denton AE, Roberts EW, Fearon DT. Stromal cells in the tumor microenvironment. Adv Exp Med Biol. 2018;1060:99–114.PubMedCrossRef
70.
71.
72.
Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia. 2016;18(10):636–46.PubMedPubMedCentralCrossRef
73.
Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313–25.PubMedCrossRef
74.
Rao Q, Chen Y, Yeh CR, Ding J, Li L, Chang C, Yeh S. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. Oncotarget. 2016;7(7):7842–55.PubMedCrossRef
75.
76.
Cheng HW, Chen YF, Wong JM, Weng CW, Chen HY, Yu SL, Chen HW, Yuan A, Chen JJ. Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway. J Exp Clin Cancer Res. 2017;36(1):27.PubMedPubMedCentralCrossRef
77.
Li D, Jiao W, Liang Z, Wang L, Chen Y, Wang Y, Liang Y, Niu H. Variation in energy metabolism arising from the effect of the tumor microenvironment on cell biological behaviors of bladder cancer cells and endothelial cells. BioFactors. 2020;46(1):64–75.PubMedCrossRef
78.
Huang Z, Zhang M, Chen G, Wang W, Zhang P, Yue Y, Guan Z, Wang X, Fan J. Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. Int J Oncol. 2019;54(5):1555–66.PubMedPubMedCentral
79.
Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019;20(6):353–67.PubMedPubMedCentralCrossRef
80.
Yang Q, Zhang AH, Miao JH, Sun H, Han Y, Yan GL, Wu FF, Wang XJ. Metabolomics biotechnology, applications, and future trends: a systematic review. RSC Adv. 2019;9(64):37245–57.PubMedPubMedCentralCrossRef
81.
Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021;39(1):41–51.PubMedCrossRef
82.
Walsh MC, Brennan L, Malthouse JP, Roche HM, Gibney MJ. Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am J Clin Nutr. 2006;84(3):531–9.PubMedCrossRef
83.
Nizioł J, Ossoliński K, Płaza-Altamer A, Kołodziej A, Ossolińska A, Ossoliński T, Ruman T. Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer. Sci Rep. 2022;12(1):15156.PubMedPubMedCentralCrossRef
84.
85.
Petrella G, Ciufolini G, Vago R, Cicero DO. The Interplay between oxidative phosphorylation and glycolysis as a potential marker of bladder cancer progression. Int J Mol Sci. 2020;21(21):8107.PubMedPubMedCentralCrossRef
86.
Rodrigues D, Pinto J, Araújo AM, Jerónimo C, Henrique R, Bastos MDL, Guedesde Pinho P, Carvalho M. GC-MS metabolomics reveals distinct profiles of low- and high-grade bladder cancer cultured cells. Metabolites. 2019;9(1):18.PubMedPubMedCentralCrossRef
87.
88.
89.
90.
Ibaragi S, Yoshioka N, Li S, Hu MG, Hirukawa S, Sadow PM, Hu GF. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription. Clin Cancer Res. 2009;15(6):1981.PubMedPubMedCentralCrossRef
91.
92.
Shu J, Huang M, Tian Q, Shui Q, Zhou Y, Chen J. Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway. J Mol Histol. 2015;46(2):157.PubMedCrossRef
93.
94.
95.
96.
Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000;10(5):359–66.PubMedCrossRef
97.
Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schuring MP, Salmon I, Gabius HJ, Pector JC, Kiss R. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol. 2003;16(5):491–504.PubMedCrossRef
98.
Roskoski R Jr. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020;151: 104567.PubMedCrossRef
99.
Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18–20.PubMedCrossRef
100.
Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest. 2009;119(5):1216–29.PubMedPubMedCentralCrossRef
101.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O’Hagan A, Avadhani A, Siefker-Radtke AO. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–48.PubMedCrossRef
102.
Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, Scagliarini S, Crocetto F, Bianco R, Formisano L. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115: 102530.PubMedCrossRef
103.
104.
El Hag M, Schmidt L, Roh M, Michael CW. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions. Diagn Cytopathol. 2016;44(4):299–304.PubMedCrossRef
105.
Xue M, Li X, Chen W. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein alpha by hypoxia inducible factor-1 alpha in bladder transitional carcinoma cells. Mol Med Rep. 2015;12(2):2121–7.PubMedCrossRef
106.
Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab. 2002;282(4):E974.PubMedCrossRef
107.
Bostrom PJ, Thoms J, Sykes J, Ahmed O, Evans A, van Rhijn BWG, Mirtti T, Stakhovskyi O, Laato M, Margel D, Pintilie M, Kuk C, Milosevic M, Zlotta AR, Bristow RG. Hypoxia marker GLUT-1 (Glucose Transporter 1) is an independent prognostic factor for survival in bladder cancer patients treated with radical cystectomy. Bladder Cancer (Amsterdam, Netherlands). 2016;2(1):101–9.PubMedCrossRef
108.
Li Y, Wang H, Tu C, Shiverick KT, Silverman DN, Frost SC. Role of hypoxia and EGF on expression, activity, localization and phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast cancer cells. Biochim Biophys Acta. 2011;1813(1):159–67.PubMedCrossRef
109.
Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat. 2018;28(10):709–12.PubMedCrossRef
110.
Miyaji E, Nishimori I, Taniuchi K, Takeuchi T, Ohtsuki Y, Onishi S. Overexpression of carbonic anhydrase-related protein VIII in human colorectal cancer. J Pathol. 2003;201(1):37–45.PubMedCrossRef
111.
112.
Tostain J, Li G, Gentil-Perret A, Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer. 2010;46(18):3141–8.PubMedCrossRef
113.
Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009;115(7):1448–58.PubMedCrossRef
114.
115.
116.
117.
Bernardo C, Costa C, Amaro T, Gonçalves M, Lopes P, Freitas R, Gärtner F, Amado F, Ferreira JA, Santos LL. Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study. Anticancer Res. 2014;34:735–44.PubMed
118.
Andreia P, Elisabete F, Cristiana G, Luís L, Rita A, Janine S, Sofia C, Beatriz P, Manuel N, Teresina A. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O -glycosylation extension. Oncotarget. 2016;7(39):63138–57.CrossRef
119.
120.
121.
Jou YC, Tsai YS, Lin CT, Tung CL, Tzai TS. Foxp3 enhances HIF-1α target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation. Oncotarget. 2016;7(40):65403–17.PubMedPubMedCentralCrossRef
122.
Lin F, Yin HB, Li XY, Zhu GM, He WY, Gou X. Bladder cancer cellsecreted exosomal miR21 activates the PI3K/AKT pathway in macrophages to promote cancer progression. Int J Oncol. 2020;56(1):151–64.PubMed
123.
Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, Clayton A. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics. 2010;9(6):1324–38.PubMedPubMedCentralCrossRef
124.
Chang C, Wang H, Liu J, Pan C, Zhang D. Porphyromonas gingivalis infection promoted the proliferation of oral squamous cell carcinoma cells through the miR-21/PDCD4/AP-1 negative signaling pathway. ACS Infect Dis. 2019;5(8):1336–47.PubMedCrossRef
125.
Tian F, Shen Y, Chen Z, Li R, Lu J, Ge Q. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene. 2016;591(2):338–43.PubMedCrossRef
126.
Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, Lim S, Nakamura M, Andersson P, Wang J, Sun Y, Dissing S, He X, Yang X, Cao Y. TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun. 2014;5:4944.PubMedCrossRef
127.
Chen C, Luo Y, He W, Zhao Y, Kong Y, Liu H, Zhong G, Li Y, Li J, Huang J, Chen R, Lin T. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J Clin Investig. 2020;130(1):404–21.PubMedCrossRef
128.
Zhao H, Wei J, Sun J. Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy. Int Immunopharmacol. 2020;89: 107101.PubMedCrossRef
129.
130.
Lamouille S, Derynck R. Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007;178(3):437–51.PubMedPubMedCentralCrossRef
131.
Su Y, Feng W, Shi J, Chen L, Huang J, Lin T. circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway. Mol Cancer. 2020;19(1):23.PubMedPubMedCentralCrossRef
132.
George SK, Tovar-Sepulveda V, Shen SS, Jian W, Zhang Y, Hilsenbeck SG, Lerner SP, Smith CL. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol. 2013;6(3):244–55.PubMedPubMedCentralCrossRef
133.
Zhang W, Borcherding N, Kolb R. IL-1 signaling in tumor microenvironment. Adv Exp Med Biol. 2020;1240:1–23.PubMedCrossRef
134.
135.
Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003;33(1):28–37.PubMedCrossRef
136.
Ou Z, Wang Y, Liu L, Li L, Chang C. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. Oncotarget. 2015;6(28):26065–78.PubMedPubMedCentralCrossRef
137.
Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CPN. interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2019;60:2290–9.
138.
Angela S, Paula S, Maxwell PJ, Catherine W, Johanna P, Rebecca G, O’Sullivan JM, Johnston PG, Waugh D. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis. 2008;6:1148–56.
139.
140.
Wang Z, Wang X, Xu Y, Li J, Zhang X, Peng Z, Hu Y, Zhao X, Dong K, Zhang B, Gao C, Zhao X, Chen H, Cai J, Bai Y, Sun Y, Shen L. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Med. 2022;20(1):133.PubMedPubMedCentralCrossRef
141.
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.PubMedPubMedCentralCrossRef
142.
Chen L, Mai W, Chen M, Hu J, Zhuo Z, Lei X, Deng L, Liu J-S, Yao N, Huang M, Peng Y, Ye W-C, Zhang D-M. Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin. Pharmacol Res. 2017;123:130–42.PubMedCrossRef
143.
Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34(4):536–48.PubMedCrossRef
144.
Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med. 2014;20(10):1199–205.PubMedCrossRef
145.
146.
Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J, Hu Y-C, Tsai M-Y, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. JNCI J Natl Cancer Inst. 2007;99(7):558–68.PubMedCrossRef
147.
Wu J-T, Han B-M, Yu S-Q, Wang H-P, Xia S-J. Androgen receptor is a potential therapeutic target for bladder cancer. Urology. 2010;75(4):820–7.PubMedCrossRef
148.
Ding G, Yu S, Cheng S, Li G, Yu Y. Androgen receptor (AR) promotes male bladder cancer cell proliferation and migration via regulating CD24 and VEGF. Am J Transl Res. 2016;8:578.PubMedPubMedCentral
149.
Inoue S, Mizushima T, Ide H, Jiang G, Goto T, Nagata Y, Netto GJ, Miyamoto H. ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling. Endocr Connect. 2018;7(12):1397–408.PubMedPubMedCentralCrossRef
150.
151.
152.
153.
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012;109(11):1716–26.PubMedCrossRef
154.
Bernardo C, Santos J, Costa C, Tavares A, Amaro T, Marques I, Gouveia MJ, Félix V, Afreixo V, Brindley PJ, Costa JM, Amado F, Helguero L, Santos LL. Estrogen receptors in urogenital schistosomiasis and bladder cancer: estrogen receptor alpha-mediated cell proliferation. Urol Oncol Semin Orig Investig. 2020;38(9):738.e23-738.e35.
155.
Hsu I, Yeh C-R, Slavin S, Miyamoto H, Netto GJ, Tsai Y-C, Muyan M, Wu X-R, Messing EM, Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer development via INPP4B inhibited Akt pathway in vitro and in vivo. Oncotarget. 2014;5(17):7917–35.PubMedPubMedCentralCrossRef
156.
Teng J, Wang Z-Y, Jarrard DF, Bjorling DE. Roles of estrogen receptor and in modulating urothelial cell proliferation. Endocr Relat Cancer. 2008;15(1):351–64.PubMedPubMedCentralCrossRef
157.
Han B, Cui D, Jing Y, Hong Y, Xia S. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch. World J Urol. 2012;30(6):861–7.PubMedCrossRef
158.
Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood, Jr DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson, Jr IM. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA. 2018;319(18):1880–8.PubMedPubMedCentralCrossRef
159.
Arora A, Pugliesi F, Zugail AS, Moschini M, Pazeto C, Macek P, Stabile A, Lanz C, Mombet A, Bennamoun M, Sanchez-Salas R, Cathelineau X. Comparing perioperative complications between laparoscopic and robotic radical cystectomy for bladder cancer. J Endourol. 2020;34(10):1033–40.PubMedCrossRef
160.
161.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9.PubMedCrossRef
162.
163.
Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.PubMedPubMedCentralCrossRef
164.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706–14.PubMedCrossRef
165.
Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360: k793.PubMedPubMedCentralCrossRef
166.
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–19.PubMedPubMedCentralCrossRef
167.
Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005;117(4):538–50.PubMedCrossRef
168.
Zhang W, Shi L, Zhao Z, Du P, Ye X, Li D, Cai Z, Han J, Cai J. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019;83(5):911–20.PubMedCrossRef
169.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedPubMedCentralCrossRef
170.
Zhang S, Liang F, Li W, Wang Q. Risk of treatment-related mortality in cancer patients treated with ipilimumab: a systematic review and meta-analysis. Eur J Cancer. 2017;83:71–9.PubMedCrossRef
171.
Weber JS, Dummer R, Pril VD, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675–82.PubMedCrossRef
172.
Zhang Z, Li D, Yun H, Liu W, Chai K, Tong J, Zeng T, Gao Z, Xie Y. CAR-T cells in the treatment of urologic neoplasms: present and future. Front Oncol. 2022;12: 915171.PubMedPubMedCentralCrossRef
173.
Nelson BE, Hong A, Jana B. Elucidation of novel molecular targets for therapeutic strategies in urothelial carcinoma: a literature review. Front Oncol. 2021;11: 705294.PubMedPubMedCentralCrossRef
174.
Zhang Y, Li Y, Cao W, Wang F, Xie X, Li Y, Wang X, Guo R, Jiang Z, Guo R. Single-cell analysis of target antigens of CAR-T reveals a potential landscape of “on-target, off-tumor toxicity.” Front Immunol. 2021;12: 799206.PubMedPubMedCentralCrossRef
175.
Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020;8(2). https://​doi.​org/​10.​1136/​jitc-2020-001673.
176.
Paterson DJ, Jefferies WA, Green JR, Brandon MR, Williams AF. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 1987;24(12):1281–90.PubMedCrossRef
177.
Yuan W, Li D, Xu L, Cai Y, Chen S, Liu Y, Xu F, Fu Z, Da P, Li D. Association of OX40L polymorphisms with sporadic breast cancer in northeast Chinese han population. PLoS ONE. 2012;7(8): e41277.CrossRef
178.
Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol. 2007;27(5):415–36.PubMedCrossRef
179.
Gulyas D, Kovacs G, Jankovics I, Meszaros L, Lorincz M, Denes B. Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model. PLoS ONE. 2022;17(7): e0270802.PubMedPubMedCentralCrossRef
180.
Gregory Alvord W, Quinones OA, Weiss JM, Stauffer J. CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8~+ T cell frequency and patient survival. Hum Immunol. 2014;75(7):614–20.PubMedCrossRef
181.
Guo J, Xiao J-J, Zhang X, Fan K-X. CD40 expression and its prognostic significance in human gastric carcinoma. Med Oncol. 2015;32(3):63.PubMedCrossRef
182.
Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Totterman TH, Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res. 2014;2(1):80–90.PubMedCrossRef
183.
Pang X, Zhang L, Wu J, Ma C, Chen W. Expression of CD40/CD40L in colon cancer, and its effect on proliferation and apoptosis of SW48 colon cancer cells. J BUON. 2017;22(4):894–9.PubMed
184.
185.
Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646–53.PubMedCrossRef
186.
Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115(18):4090–5.PubMedCrossRef
187.
Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol. 2011;60(2):344–9.PubMedCrossRef
188.
Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13(8):810–6.PubMedCrossRef
189.
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013;11(4):477–83.PubMedPubMedCentralCrossRef
190.
Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, Mukherjee SD, Wang L, Blattler C, Wright JJ, Moore MJ. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs. 2011;29(5):1045–9.PubMedCrossRef
191.
192.
Investigators Rs. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–2277. https://​doi.​org/​10.​1016/​S0140-6736(17)32365-6.
193.
194.
Nadal R, Mortazavi A, Stein MN, Pal SK, Lee DK, Parnes HL, Ning Y-M, Cordes LM, Bagheri M, Thompson R, Mayfield C, Steinberg SM, Monk P, Lara PN, Costello R, Agarwal PK, Bottaro DP, Dahut WL, Apolo AB. Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI). J Clin Oncol. 2018. https://​doi.​org/​10.​1200/​JCO.​2018.​36.​15_​suppl.​4528.CrossRef
195.
196.
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37.PubMedCrossRef
197.
Tarantino P, Pestana RC, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria J-C, Curigliano G. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2021;72(2):165–182. https://​doi.​org/​10.​3322/​caac.​21705.
198.
Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–23.PubMedCrossRef
199.
Sarfaty M, Rosenberg JE. Antibody-drug conjugates in urothelial carcinomas. Curr Oncol Rep. 2020;22(2):13.PubMedCrossRef
200.
201.
202.
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flechon A, Jain R, Agarwal N, Bupathi M, Barthélémy P, Beuzeboc P, Palmbos PL, Kyriakopoulos C, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021. https://​doi.​org/​10.​1200/​JCO.​20.​03489.CrossRefPubMedPubMedCentral
203.
204.
Tan B, Shi X, Zhang J, Qin J, Zhang N, Ren H, Qian M, Siwko S, Carmon K, Liu Q, Han H, Du B, Liu M. Inhibition of Rspo-Lgr4 facilitates checkpoint blockade therapy by switching macrophage polarization. Cancer Res. 2018;78(17):4929–42.PubMedCrossRef
205.
Goswami KK, Sarkar M, Ghosh S, Saha A, Ghosh T, Guha I, Barik S, Banerjee S, Roy S, Bose A, Dasgupta P, Baral R. Neem leaf glycoprotein regulates function of tumor associated M2 macrophages in hypoxic tumor core: critical role of IL-10/STAT3 signaling. Mol Immunol. 2016;80:1–10.PubMedCrossRef
206.
Qiu S, Deng L, Liao X, Nie L, Qi F, Jin K, Tu X, Zheng X, Li J, Liu L, Liu Z, Bao Y, Ai J, Lin T, Yang L, Wei Q. Tumor-associated macrophages promote bladder tumor growth through PI3K/AKT signal induced by collagen. Cancer Sci. 2019;110(7):2110–8.PubMedPubMedCentralCrossRef
207.
Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Toritsuka M, Kishimoto T, Rosser CJ, Fujimoto K. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia. 2016;18(10):636–46.PubMedPubMedCentralCrossRef
208.
Chen C, He W, Huang J, Wang B, Li H, Cai Q, Su F, Bi J, Liu H, Zhang B, Jiang N, Zhong G, Zhao Y, Dong W, Lin T. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018;9(1):3826.PubMedPubMedCentralCrossRef
209.
Martínez VG, Rubio C, Martínez-Fernández M, Segovia C, López-Calderón F, Garín MI, Teijeira A, Munera-Maravilla E, Varas A, Sacedón R, Guerrero F, Villacampa F, de la Rosa F, Castellano D, López-Collazo E, Paramio JM, Vicente Á, Dueñas M. BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer. Clin Cancer Res. 2017;23(23):7388–99.PubMedCrossRef
210.
Gunes M, Gecit I, Pirincci N, Kemik AS, Purisa S, Ceylan K, Aslan M. Plasma human neutrophil proteins-1, -2, and -3 levels in patients with bladder cancer. J Cancer Res Clin Oncol. 2013;139(2):195–9.PubMedCrossRef
211.
Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, Kimura S, Shariat SF. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol. 2018;36(9):389–99.PubMedCrossRef
212.
Liu PF, Cao YW, Zhang SD, Zhao Y, Liu XG, Shi HQ, Hu KY, Zhu GQ, Ma B, Niu HT. A bladder cancer microenvironment simulation system based on a microfluidic co-culture model. Oncotarget. 2015;6(35):37695–705.PubMedPubMedCentralCrossRef
213.
Kawakami Y, Haas GP, Lotze MT. Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4. J Immunother Emphasis Tumor Immunol. 1993;14(4):336–47.PubMedCrossRef
214.
Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19(1):137.PubMedPubMedCentralCrossRef
215.
Reyes RM, Zhang C, Deng Y, Ji N, Mukherjee N, Padron AS, Clark CA, Svatek RS, Curiel TJ. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. OncoImmunology. 2021;10(1):2006529.PubMedPubMedCentralCrossRef
216.
Xu Y, Zeng H, Jin K, Liu Z, Zhu Y, Xu L, Wang Z, Chang Y, Xu J. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer. 2022;10(3): e003416.PubMedPubMedCentralCrossRef
217.
Suttmann H, Jacobsen M, Reiss K, Jocham D, Böhle A, Brandau S. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol. 2004;172(4 Part 1):1490–5.PubMedCrossRef
218.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021;79(2):214–21.PubMedCrossRef
219.
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005; 48(2): 202–5; discussion 205–6.
220.
Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA, O’Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83(6):486–494.https://​doi.​org/​10.​1016/​j.​eururo.​2023.​01.​017.
221.
Fontes MS, Vargas Pivato de Almeida D, Cavalin C, Tagawa ST. Targeted therapy for locally advanced or metastatic urothelial cancer (mUC): therapeutic potential of sacituzumab govitecan. Onco Targets Ther. 2022;15:1531–42.PubMedPubMedCentralCrossRef
222.
Metadata
Title
Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review
Authors
Liu Tang
Haifei Xu
Tong Wu
Wenhao Wu
Yuhao Lu
Jijia Gu
Xiaoling Wang
Mei Zhou
Qiuyang Chen
Xuan Sun
Hongzhou Cai
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00902-8

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue

Review

Artificial intelligence assisted diagnosis of early tc markers and its application

Review

Polyamines: the pivotal amines in influencing the tumor microenvironment

Research

Heterogeneous expression of ARID1A in colorectal cancer indicates distinguish immune landscape and efficacy of immunotherapy

Review

MAP3K4 kinase action and dual role in cancer

Research

Bilateral adrenal neuroblastoma: peculiar pattern of a rare pediatric presentation

Review

Novel insights into the roles of migrasome in cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits